No Data
Kangzhi Pharmaceutical: Report for the third quarter of 2024
Honz Pharmaceutical (300086.SZ): Currently, the company has a business of importing active pharmaceutical ingredients.
On September 27, Honz Pharmaceutical (300086.SZ) stated on the investor interaction platform that the company currently has a business of importing active pharmaceutical ingredients. In order to benefit from the relevant policies of Hainan Free Trade Port, the company has applied for and obtained the "AEO Advanced Certified Enterprise Certificate." Enterprises certified by AEO can carry out mutual recognition cooperation with customs of various countries, achieve credit management by global customs, enjoy preferential treatment provided by global customs, which will promote the cooperative development of the company's foreign trade.
Honz Pharmaceutical Logs About 30 Million Yuan in Damages Amid Typhoon Makar; Shares Up 20%
Honz pharmaceutical (300086.SZ): Expected to suffer asset losses of approximately 30 million yuan due to the impact of typhoon disaster.
Gelonghui, September 11th | HONZ Pharmaceutical (300086.SZ) announced that on September 6, 2024, Hainan was hit by Super Typhoon "Capricorn", the 11th super typhoon of the year. HONZ Pharmaceutical Co., Ltd. (hereinafter referred to as the "company") located in Haikou, Hainan production base, suffered losses to some assets due to the combined impact of this typhoon and heavy rain. As of the disclosure date of the announcement, the company's resumption of work is progressing in an orderly manner. At present, the company's inventory is relatively sufficient, and this disaster does not temporarily affect the company's normal supply and sales. However, due to damage to the factory buildings, machinery and equipment, there is a certain impact on the normal production in the company's workshop. Due to network issues
Honz Pharmaceutical: Half-year report for the year 2024.
Honz Pharmaceutical: Summary of Half-Year Report in 2024.
Honz Pharmaceutical Co., Ltd.'s (SZSE:300086) Business Is Yet to Catch Up With Its Share PriceNo Data
No Data
